Cargando…
Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
BACKGROUND: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. METHODS:...
Autores principales: | Nakano, Kenji, Motoi, Noriko, Tomomatsu, Junichi, Gokita, Tabu, Ae, Keisuke, Tanizawa, Taisuke, Matsumoto, Seiichi, Takahashi, Shunji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035441/ https://www.ncbi.nlm.nih.gov/pubmed/27663525 http://dx.doi.org/10.1186/s12885-016-2786-z |
Ejemplares similares
-
A Clinicopathological Analysis of Soft Tissue Sarcoma with Telangiectatic Changes
por: Kobayashi, Hiroshi, et al.
Publicado: (2015) -
Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019) -
Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
por: Sato, Yasuyoshi, et al.
Publicado: (2021) -
Risk factors for distant metastasis of dermatofibrosarcoma protuberans
por: Hayakawa, Keiko, et al.
Publicado: (2016) -
Osteosarcoma arising from acetabulum extended to femoral head through round ligament: a case report
por: Sasaki, Toru, et al.
Publicado: (2020)